Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
TMS Co., Ltd. ( (JP:4891) ) just unveiled an update.
TMS Co., Ltd. has submitted a Clinical Trial Plan Notification to Japan’s Pharmaceuticals and Medical Devices Agency for the ORION study, which will evaluate the effects of JX10 on acute ischemic stroke patients. This submission marks a significant step in the global study led by Corxel Pharmaceuticals, aiming to extend treatment opportunities beyond the current standard timeframe, although the financial impact on TMS for this fiscal year is expected to be minor.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformative medicines for serious diseases with high unmet medical needs. The company focuses on a pipeline of small molecule compounds known as SMTPs, derived from a fungus, and has established partnerships with leading academic institutions in Japan to bridge academic discoveries with the global pharmaceutical market.
YTD Price Performance: -39.91%
Average Trading Volume: 1,844,090
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.71B
For a thorough assessment of 4891 stock, go to TipRanks’ Stock Analysis page.